A new solution for age-related farsightedness without glasses?

Presbyopia, or age-related farsightedness, affects almost everyone after the age of 45, although it can occur earlier. Until now, people have been treated with reading glasses, contact lenses, or surgery. But recently, the U.S. Food and Drug Administration (FDA) approved a new, noninvasive solution.

Lenz Therapeutics' innovative Vizz eye drops offer a temporary solution without the need for glasses. The drops actually contain aceclidine, which constricts the pupils and creates a so-called "pinhole" effect, thereby improving visual acuity. The effect occurs in about 30 minutes and lasts up to 10 hours, which is longer than Vuity drops (4 to 6 hours). An important advantage of Vizz drops is that they do not impair distance vision.

Clinical results are promising, side effects are mild
The FDA approval was based on three studies involving more than 680 people and a total of more than 30,000 treatment days. CLARITY-1 and CLARITY-2 showed improvement in near vision, while CLARITY-3 demonstrated good tolerability over a six-month period. The most common side effects were mild. Some people reported side effects such as eye irritation, decreased vision in low light, headaches, and redness.

Effectiveness in early stage presbyopia
There are no official recommendations regarding the diopter, but eye experts say that the drops are most effective in the early stages. In practice, this means between the ages of 45 and 55. The therapeutic effects are reduced in low light due to the constantly constricted pupils.

USA: Iwall end of 2025, price may be high
The first samples of Lenz Therapeutics' Vizz eye drops will be available to doctors in the US in October 2025, with general sales expected to begin by the end of the year. In Europe, the product will be marketed by Théa, but the timeline is not yet known. The price is likely to be similar to Vuity, at around €93 per month.